OPKO Health, Inc.
OPK Healthcare Diagnostics & Research
OPKO Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.9 million, down 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 4.32%, EPS grew 94.7%, free cash flow grew 46.5% and total debt rose 6.37%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow OPK
OPKO Health, Inc. (OPK) P/E ratio
OPKO Health, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 120× (February 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 79.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| WGS GeneDx Holdings Corp. compare | n/m |
| CSTL Castle Biosciences, Inc. compare | n/m |
| NEO NeoGenomics, Inc. compare | n/m |
| MYGN Myriad Genetics, Inc. compare | n/m |
| FLGT Fulgent Genetics, Inc. compare | n/m |
| PSNL Personalis, Inc. compare | n/m |
| OPK OPKO Health, Inc. | n/m |
| CDNA CareDx, Inc. compare | 29.7× |
| VCYT Veracyte, Inc. compare | 29.9× |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)